Abstract
DARE-BV1 is a novel, highly viscous single dose 2% clindamycin phosphate vaginal gel being investigated as a new treatment for bacterial vaginosis. In a recently completed large, randomized multi-center, placebo-controlled study, DARE-BV1 demonstrated a clinical cure of 70.5% vs. 35.6% in the placebo group (p < 0.001) at Days 21-30. The objective of this study was to determine the systemic and vaginal pharmacokinetics (PK) of DARE-BV1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
